Biodistribution and radiation dosimetry in humans of a new PET ligand, 18F-PBR06, to image translocator protein (18 kDa)

Yota Fujimura, Yasuyuki Kimura, Fabrice G. Siḿeon, Leah P. Dickstein, Victor W. Pike, Robert B. Innis, Masahiro Fujita

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


As a PET biomarker for inflammation, translocator protein (18 kDa) (TSPO) can be measured with an 18F-labeled aryloxyanilide, 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline ( 18F-PBR06), in the human brain. The objective of this study was to estimate the radiation absorbed doses of 18F-PBR06 based on biodistribution data in humans. Methods: After the injection of 18F-PBR06, images were acquired from head to thigh in 7 healthy humans. Urine was collected at various time points. Radiation absorbed doses were estimated by the MIRD scheme. Results: Moderate to high levels of radioactivity were observed in organs with high densities of TSPO and in organs of metabolism and excretion. Bone had low levels of radioactivity. The effective dose was 18.5 μSv/MBq. Conclusion: The effective dose of 18F-PBR06, compared with other 18F radioligands, was moderate. This radioligand had negligible defluorination, as indirectly assessed by bone radioactivity. Doses to the gallbladder wall and spleen may limit the amount of permissible injected radioactivity.

Original languageEnglish (US)
Pages (from-to)145-149
Number of pages5
JournalJournal of Nuclear Medicine
Issue number1
StatePublished - Jan 1 2010


  • Aryloxyanilide
  • Defluorination
  • Inflammation
  • MIRD scheme
  • Microglia

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Biodistribution and radiation dosimetry in humans of a new PET ligand, <sup>18</sup>F-PBR06, to image translocator protein (18 kDa)'. Together they form a unique fingerprint.

Cite this